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Abstract
Background: Discordance between patient and physician ratings of rheumatoid arthritis (RA) severity occurs in
clinical practice and correlates with pain scores and measurements of joint disease. However, information is lacking
on whether discordance impacts patients’ ability to work. We evaluated the discordance between patient and
physician ratings of RA disease activity before and after treatment with etanercept and investigated the associations
between discordance, clinical outcomes, and work productivity.
Methods: In the PRESERVE clinical trial, patients with moderate RA received open-label etanercept 50 mg once
weekly plus methotrexate for 36 weeks. Baseline and week-36 disease characteristics and clinical and work
productivity outcomes were categorized according to week-36 concordance category, defined as positive
discordance (patient global assessment – physician global assessment ≥2), negative discordance (patient global
assessment – physician global assessment ≤ –2), and concordance (absolute difference between the two disease
activity assessments = 0 or 1). Correlations between discordance, clinical outcomes, and predictors of discordance
were determined.
Results: At baseline, 520/762 (68.2 %) patient and physician global assessment scores were concordant, 194 (25.5 %)
were positively discordant, and 48 (6.3 %) were negatively discordant. After 36 weeks of therapy, 556/763 (72.9 %)
scores were concordant, 189 (24.8 %) were positively discordant, and 18 (2.4 %) were negatively discordant. Patients
with week-36 concordance had the best 36-week clinical and patient-reported outcomes, and overall, the greatest
improvement between baseline and week 36. Baseline pain, swollen joint count, duration of morning stiffness, fatigue,
and patient general health significantly correlated with week-36 discordance, p < 0.0001 to p < 0.05. Additionally,
baseline pain, patient general health, and C-reactive protein were predictors of week-36 discordance (odds ratios 1.22,
1.02, and 0.98, respectively). For the employed patients, percent impairment while working and percent overall work
impairment were highest (greatest impairment) at baseline and 36 weeks in the group with positive discordance.
Conclusions: The percentage of patients with concordance increased after 36 weeks of treatment with etanercept,
with concordant patients demonstrating the greatest improvement in clinical and patient-reported outcomes.
Discordance correlated with several measures of disease activity and was associated with decreased work productivity.
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Background
Assessments of disease activity may differ between pa-
tients and physicians. Studies have shown that a discrep-
ancy occurs in approximately one third of cases;
however, this can vary depending on how it is measured
[1–6]. Discordance occurs in many chronic illnesses, in-
cluding rheumatoid arthritis (RA), and may be present
before treatment starts or during the course of therapy
[1–15]. In RA, physicians tend to rate disease activity
lower than patients; however, scoring differences in both
directions have been reported [1–7, 9, 11–15]. Several
reasons have been proposed for these differences, in-
cluding functional impairment, limited knowledge about
health, and differences in the signs and symptoms on
which patients and physicians focus. Importantly, pa-
tients primarily concentrate on pain and tenderness
when rating RA disease activity, and physicians focus on
swollen joints and C-reactive protein (CRP) or erythro-
cyte sedimentation rate (ESR) [3–5, 9, 11–13, 15, 16]. As
pain may be present even if the disease is controlled, the
difference between patient and physician viewpoints may
be exaggerated when the disease is not active [15]. This
may be the case particularly in long-standing disease
when joint damage and damage-related disability are
present. It is also possible that patients self-assess signs
and symptoms of other comorbidities and attribute them
to their RA. Finally, physicians may relate the condition
of one patient to that of the many patients seen over the
years, while individual patients may have little more than
their own situation and wellbeing as comparator.
A better understanding of patient and physician bias
(conscious and unconscious), perceptions, judgment,
beliefs about what medicines can or cannot do, and dis-
connects in the assessment of RA signs and symptoms
may enable clinicians to more effectively communicate
with patients, improve treatment outcomes, and help pa-
tients achieve their varied treatment goals [16]. This
includes a component of active listening and openness
to patient input. In other chronic diseases, such strat-
egies, including open-ended discussions with patients,
have demonstrated an increased ability to identify
patients at risk of non-adherence and allow for better
alignment with patient goals [17, 18].
Decrease in pain and improvement of physical func-
tion may not be the only objectives for patients. Patients
may also be concerned about the impact of RA on their
overall activities and their ability to work. Studies have
demonstrated that RA, whether early or late in the dis-
ease course, affects patients’ ability to work, which in
turn can lead to presenteeism, absenteeism, unemploy-
ment, income loss, and early retirement [19–29].
To our knowledge, no published studies have evalu-
ated whether discordance in the assessment of disease
activity is connected to presenteeism, absenteeism, and
work impairment in patients with RA. In addition,
differences in assessments of disease activity in RA have
not been rigorously examined in clinical trial popula-
tions. Publications to date have evaluated mostly clinic
patients in observational studies; consequently, the
results are often complicated by the fact that the patients
did not receive identical therapy or monitoring and
came from a single center and/or academic environ-
ment, in contrast to a large, multicenter clinical trial [1–
7, 9, 11–13, 15].
The PRESERVE trial (ClinicalTrials.gov identifier,
NCT00565409) was a multicenter two-period trial in
adults with moderate RA [30]. Period 1 was the open-
label, single treatment phase of the trial that evaluated
responses to combination etanercept and methotrexate
therapy for 36 weeks, and period 2 was the randomized,
double-blind phase that investigated the outcomes of
dose reduction or withdrawal of etanercept. This analysis
only includes data from period 1, thereby focusing on
discordance in patients with moderate disease activity
who were being treated to a target of low disease
activity. This report examines (1) the difference, i.e.,
discordance, between patients’ and physicians’ global as-
sessments of disease activity at baseline and 36 weeks;
(2) correlations between clinical parameters and discord-
ance of global assessments at baseline and week 36; (3)
baseline predictors of week-36 discordance; and (4)
whether week-36 discordance is associated with work
productivity.
Methods
Details of the PRESERVE trial have been presented else-
where [30]. In brief, patients were 18–70 years of age
with a diagnosis of RA based on the 1987 American
College of Rheumatology criteria. Patients had a moder-
ate disease activity score based on a 28-joint count
(DAS28 >3.2 and ≤5.1) and were enrolled at 80 centers
in Europe, Asia, Australia, and Latin America. Eligible
patients were required to have taken stable doses of oral
methotrexate 15–25 mg/week for at least 8 weeks prior
to receiving 50 mg open-label etanercept once weekly
plus methotrexate ≥10 mg/week for the 36 weeks of
period 1. Exclusion criteria included use of disease-
modifying anti-rheumatic drugs (DMARDs) other than
methotrexate within 28 days before baseline or current
or previous use of a biologic DMARD for RA.
The study was conducted in accordance with the
International Conference on Harmonisation guideline
for good clinical practice and the ethical principles of
the Declaration of Helsinki. Written informed consent
was obtained from all patients prior to enrollment.
The study protocol and all consent forms were reviewed
and approved by an institutional review board or an
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independent ethics committee at each participating center
(see “Acknowledgments” for details).
Patients and physicians completed their respective glo-
bal assessments of disease activity at baseline and weeks
4, 8, 12, 20, 28, and 36. Patients were blinded to phys-
ician global assessments and physicians were blinded to
patient global assessments. The physician global assess-
ment was performed prior to the physician having access
to the C-reactive protein (CRP) levels from that visit.
The global assessments used a numerical rating scale on
which respondents were asked to rate disease activity by
circling a number ranging from 0 (no disease activity) to
10 (extreme disease activity) [31]. At baseline and week
36, mean differences between patient and physician
scores were categorized as positive discordance (patient
global assessment – physician global assessment ≥2),
negative discordance (patient global assessment – phys-
ician global assessment ≤ –2), or concordance (absolute
difference between the two disease activity scores = 0 or
1). The cutoff of 2 was chosen by rounding to the closest
whole number above the one standard deviation of 1.72
obtained from the mean difference between patient and
physician global assessments.
Concordance/discordance was determined for all
patients, and for the subgroup of patients who achieved
all three outcomes of swollen joint count (SJC) ≤1, ten-
der joint count (TJC) ≤1, and CRP ≤1 mg/dL at
36 weeks, and for those patients who achieved the
Boolean-based definition of clinical remission (SJC ≤1,
TJC ≤1, CRP ≤1 mg/dL, and patient global assessment
≤1) [32]. Concordance/discordance was also determined
for the patients who achieved remission according to the
clinical disease activity index (CDAI ≤2.8) at 36 weeks.
Additionally, the rates of Boolean and CDAI remission
were evaluated according to baseline and week-36 dis-
cordance status.
Endpoints at 36 weeks according to concordance/dis-
cordance category included DAS28, CRP, TJC, SJC,
health assessment questionnaire disability index (HAQ-
DI), erythrocyte sedimentation rate (ESR), patient and
physician global assessments, duration of morning joint
stiffness, brief pain inventory (BPI), simplified disease ac-
tivity index (SDAI), CDAI, patient general health visual
analog scale (VAS), and functional assessment of chronic
illness therapy-fatigue (FACIT-fatigue). Additionally, for
the subgroup of patients who achieved the three out-
comes of SJC ≤1, TJC ≤1, and CRP ≤1 mg/dL at
36 weeks, the measurement of the modified total Sharp
score was characterized by concordance category.
Patient global assessment and patient general health
VAS are assessments with several important differences.
The patient global assessment requests that patients
measure overall arthritis activity by asking them to circle
a number between 0 and 10, with 0 indicating no
arthritis activity and 10 indicating extreme activity. The
patient general health VAS asks patients to indicate, “in
general how would you rate your health over the last 2–
3 weeks?” Patients place a mark on a 100-mm line, with
0 mm meaning “very well” and 100 mm meaning “ex-
tremely bad.” Thus, the patient global assessment mea-
sures arthritis disease activity and the patient general
health VAS measures overall health.
Additionally, the extent to which work productivity ac-
tivity impairment was associated with discordance was
determined for each component of the work productivity
activity impairment questionnaire for RA (WPAI:RA).
The WPAI:RA is a validated tool for measuring work
productivity that was used in the PRESERVE trial [33],
consisting of four components: activity impairment, ab-
senteeism, presenteeism, and overall work impairment
[34, 35]. The questionnaire focuses on impairment due
to RA only. Activity impairment includes patients not
employed outside the home; the other components are
measured for employed patients only. Absenteeism is
missed work days due to health, and presenteeism is a
reduction of productivity or diminished work capacity
while at work [35]. Overall work impairment is calcu-
lated using both absenteeism and presenteeism. Each
component of the WPAI:RA is scored from 0–100 %;
higher scores indicate a worse outcome.
Statistical analysis
The analyses included patients in the period 1 popula-
tion who received at least one dose of study medication
and had data at baseline and week 36. Missing data at
week 36 were not imputed, rather the observed case ap-
proach was used. Descriptive statistics were used to
characterize differences in patient demographics, disease
characteristics, and clinical endpoints among concordant
and discordant groups. P values for demographic and
baseline disease characteristics were generated using the
F test from analysis of variance for continuous variables;
Cochran-Mantel-Haenszel test or Fisher’s exact test was
used for categorical variables. The proportion of patients
who shifted between baseline and week-36 concordance
categories was determined.
Correlations between discordance (analyzed as con-
tinuous parameters) and clinical endpoints were deter-
mined using Pearson’s r correlation. Stepwise logistic
regression was performed to determine significant base-
line predictors of week-36 discordance. As binomial lo-
gistic regression requires two categories, the concordant
and negative discordance groups were combined into
one category and compared with positive discordance.
The following parameters were included in the stepwise
logistic regression analyses of baseline predictors: age,
sex, disease duration, race, prior alcohol and tobacco
use, rheumatoid factor status, body mass index, TJC-28,
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SJC-28, CRP, ESR, HAQ-DI, DAS28, CDAI, SDAI,
FACIT-fatigue, patient general health, BPI, and duration
of morning stiffness. Odds ratios were calculated to de-
scribe the strength of the association between baseline
or week-36 parameters and the two discordance categor-
ies at 36 weeks.
Descriptive statistics for change from baseline were de-
termined for the WPAI:RA for each concordance group.
Three of the four outcome scores (absenteeism, present-
eeism, and overall work impairment due to RA) were
evaluated for the subgroup of patients who were
employed at both baseline and 36 weeks; activity impair-




The PRESERVE trial enrolled 834 patients [30]. The first
period (36 weeks) of the study was completed by 756
patients (90.6 %); 77 patients discontinued and results
from one patient were not included due to a data dis-
crepancy. This analysis includes patients in the period-1
population with data to week 36 (n = 763). There were
13 patients who did not complete period 1 but had
week-36 data (e.g., their 28-week visit occurred late and
was assigned to week 36), and 6 patients completed
period 1 but did not have week-36 data (e.g., their week-
36 visit occurred early and was assigned to week 28);
thus, the difference of 7 patients between period-1 com-
pleters and patients with week-36 data. Mean (SD) age
was 48.2 (11.9) years, 82.8 % were female, 74.4 % were
white, and duration of RA symptoms was 7.0 (6.9) years.
Additional baseline disease characteristics are provided
in Table 1.
Concordance
At baseline, 520/762 patient and physician global assess-
ment scores (68.2 %; one patient had no baseline data
available for one of the measures) were concordant (i.e.,
the difference between the scores was 0 (34.3 %) or 1
(34.0 %)). The number of patients with positively and
negatively discordant scores was 194 (25.5 %) and 48
(6.3 %), respectively. Table 2 lists disease characteristics
at baseline, week 36, and the change between baseline
and week 36 for all patients, according to week-36 con-
cordance category. At baseline, several clinical and
patient-reported characteristics differed significantly ac-
cording to concordance/discordance category: CRP, SJC-
28, duration of morning stiffness, BPI, FACIT-fatigue,
CDAI, SDAI, patient and physician global assessment,
and patient general health. The values for most of these
characteristics indicated more severe disease in the dis-
cordant than in the concordant patients. The exception
was CRP; this was highest in the patients with concord-
ance, with a mean (SD) of 13.4 (17.7) mg/L versus 9.9
(13.9) mg/L for positive discordance and 8.1 (7.1) mg/L
for negative discordance.
After 36 weeks of therapy, concordance increased to
556/763 patients (72.9 %); the number of patients with
positively and negatively discordant scores decreased to
189 (24.8 %) and 18 (2.4 %), respectively. Improvement
between baseline and week 36 differed significantly ac-
cording to concordance/discordance status for DAS28,
CRP, ESR, TJC, SJC, BPI, HAQ-DI, FACIT-fatigue,
Table 1 Demographics and baseline disease characteristics according to week-36 concordance category
Week 36 (n = 763)
Positive discordance (n = 189) Concordance (n = 556) Negative discordance (n = 18)
Age, years, mean (SD) 48.8 (11.5) 47.9 (12.1) 49.8 (10.8)
Female, n (%) 160 (84.7) 455 (81.8) 17 (94.4)
White, n (%) 130 (68.8) 424 (76.3) 14 (77.8)
Prior alcohol, n (%) 22 (11.6) 64 (11.5) 2 (11.1)
Prior tobacco, n (%) 39 (20.6) 98 (17.6) 4 (22.2)
Rheumatoid factor+, n (%) 130 (68.8) 411 (73.9) 11 (61.1)
Duration of disease symptoms, years, mean (SD) 6.8 (6.9) 6.9 (6.9) 9.0 (8.1)
Weekly dose of methotrexate, mg, mean (SD) 16.4 (2.4) 16.5 (2.8) 15.8 (1.9)
Prior treatment, n (%)
Methotrexate 189 (100.0) 556 (100.0) 18 (100.0)
DMARDs other than methotrexate 46 (24.3) 145 (26.1) 8 (44.4)
Glucocorticoids 117 (61.9) 325 (58.5) 10 (55.6)
NSAIDs 133 (70.4) 422 (75.9) 14 (77.8)
Positive discordance: patient global assessment – physician global assessment ≥2. Negative discordance: patient global assessment – physician global
assessment ≤ –2. Concordance: patient global assessment – physician global assessment = 0 or 1. SD standard deviation, DMARDs disease-modifying anti-rheumatic
drugs, NSAIDs nonsteroidal anti-inflammatory drugs
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Table 2 Disease characteristics at baseline and week 36, according to week-36 concordance category
Week 36 (n = 763)







DAS28 BL 4.4 (0.4) 4.4 (0.4) 4.5 (0.4) 0.2356
Week 36 2.8 (1.1) 2.2 (0.9) 3.1 (1.3) <0.0001
Δ BL to wk 36 −1.6 (1.0) −2.2 (0.9) −1.4 (1.3) <0.0001
CRP, mg/L BL 9.9 (13.9) 13.4 (17.7) 8.1 (7.1) 0.0256
Week 36 6.4 (8.2) 6.4 (7.9) 7.6 (12.0) 0.8036
Δ BL to wk 36 −3.4 (14.7) −7.0 (17.0) −0.4 (9.8) 0.0123
CRP, mg/L, median BL 4.6 5.9 4.0
Week 36 4.0 4.0 4.0
Δ BL to wk 36 0 −1 0
ESR, mm/h BL 21.0 (13.9) 22.9 (13.1) 20.2 (10.5) 0.1652
Week 36 13.4 (13.1) 11.8 (9.5) 15.0 (10.5) 0.1083
Δ BL to wk 36 −7.6 (11.2) −11.1 (12.6) −5.2 (10.7) 0.0006
TJC (0–28) BL 5.0 (2.6) 5.0 (2.8) 6.0 (3.5) 0.3502
Week 36 1.8 (2.5) 1.1 (2.2) 4.0 (5.6) <0.0001
Δ BL to wk 36 −3.3 (3.4) −4.0 (3.2) −2.0 (6.3) 0.0039
SJC (0–28) BL 3.5 (2.3) 4.0 (2.7) 4.8 (3.3) 0.0227
Week 36 1.1 (1.9) 0.9 (1.9) 3.9 (4.3) <0.0001
Δ BL to wk 36 −2.3 (2.5) −3.1 (2.6) −0.9 (5.0) <0.0001
Duration of morning joint stiffness, min BL 227 (384) 158 (314) 242 (472) 0.0453
Week 36 78 (164) 39 (166) 67 (144) 0.0191
Δ BL to wk 36 −148 (370) −120 (324) −175 (515) 0.5315
BPI (0–10) BL 4.7 (2.1) 3.7 (1.9) 3.9 (2.1) <0.0001
Week 36 3.2 (2.2) 1.1 (1.3) 1.8 (1.6) <0.0001
Δ BL to wk 36 −1.5 (2.4) −2.6 (2.1) −2.1 (2.5) <0.0001
HAQ-DI (0–3) BL 1.2 (0.6) 1.1 (0.6) 1.2 (0.7) 0.1458
Week 36 0.9 (0.6) 0.5 (0.5) 0.7 (0.6) <0.0001
Δ BL to wk 36 −0.3 (0.6) −0.7 (0.5) −0.5 (0.5) <0.0001
FACIT-fatigueb (0–52) BL 30.8 (9.3) 33.7 (9.4) 29.7 (10.0) 0.0006
Week 36 35.7 (9.5) 43.1 (8.0) 39.1 (9.8) <0.0001
Δ BL to wk 36 4.9 (9.4) 9.4 (8.8) 9.3 (11.4) <0.0001
CDAI (0–76) BL 18.1 (4.5) 17.6 (5.0) 21.2 (6.3) 0.0049
Week 36 8.7 (5.8) 4.7 (5.1) 13.6 (10.1) <0.0001
Δ BL to wk 36 −9.5 (6.5) −12.9 (6.4) −7.6 (12.0) <0.0001
SDAI (0–86) BL 19.2 (4.6) 18.9 (5.2) 22.0 (6.2) 0.0382
Week 36 9.4 (5.9) 5.3 (5.3) 14.4 (10.5) <0.0001
Δ BL to wk 36 −9.8 (6.4) −13.6 (6.5) −7.6 (12.2) <0.0001
Patient global assessment (0–10) BL 5.5 (1.6) 4.6 (1.7) 5.2 (2.0) <0.0001
Week 36 4.5 (1.8) 1.5 (1.2) 1.4 (1.1) <0.0001
Δ BL to wk 36 −1.0 (2.2) −3.1 (1.9) −3.8 (2.2) <0.0001
Physician global assessment (0–10) BL 4.2 (1.4) 4.0 (1.3) 5.2 (1.5) 0.0002
Week 36 1.4 (1.2) 1.3 (1.1) 4.3 (2.1) <0.0001
Δ BL to wk 36 −2.9 (1.6) −2.7 (1.5) −0.9 (2.9) <0.0001
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CDAI, SDAI, patient and physician global assessment,
and patient general health (p < 0.05 for change in CRP
and TJC; p < 0.001 for ESR; and p < 0.0001 for all others;
Table 2). Patients with concordant scores at week 36 had
the best 36-week clinical and patient-reported outcomes,
and for most measurements, the greatest improvement
between baseline and week 36, compared with patients
with positively or negatively discordant scores.
At week 36, patients with negative discordance exhib-
ited the highest values of DAS28, CRP, ESR, TJC, SJC,
CDAI, and SDAI, suggesting that physicians, more than
their patients, may have looked at “objective” disease ac-
tivity measures when determining their global assess-
ment. In contrast, patients with positive discordance had
the longest morning joint stiffness and worst values for
BPI, HAQ-DI, FACIT-fatigue, and patient general health,
suggesting that they, more than their physicians, focused
on subjective outcomes when determining their global
assessment.
Most patients who were concordant at the beginning
of the study remained concordant at 36 weeks (Fig. 1).
For the patients with positive or negative discordance at
baseline, the greatest shift at 36 weeks was to concord-
ance. The smallest shift from any category was to nega-
tive discordance.
Disease remission
Subgroup analysis results indicated that 442/755 patients
(58.5 %) achieved SJC and TJC ≤1 and CRP ≤1 mg/dL at
week 36. Of those 442 patients, 255 (57.7 %) also had a
patient global assessment ≤1, thus meeting the Boolean-
based criteria for clinical remission. Interestingly, the
remaining 187 patients (42.3 %) had a patient global as-
sessment >1, suggesting that these patients did not be-
lieve they were doing as well, or indeed were not doing
as well as the objective criteria seemed to indicate,
potentially attributable to their long disease duration.
Of the 255 patients who met Boolean remission cri-
teria at week 36, 250 patients (98.0 %) were concordant,
5 (2.0 %) were negatively discordant, and none were
positively discordant. However, of the 187 patients who
had SJC and TJC ≤1, CRP ≤1 mg/dL, and patient global
assessment >1, only 93 (49.7 %) were concordant; 2
(1.1 %) were negatively discordant, and 92 (49.2 %) were
positively discordant. The patients who met Boolean
remission criteria demonstrated greater improvement in
clinical and patient-reported outcomes between baseline
and week 36 than the patients with SJC and TJC ≤1,
CRP ≤1 mg/dL, and patient global assessment >1. This
was particularly true for the outcomes of patient general
health and FACIT-fatigue (data not shown).
In comparison, 205/762 patients (26.9 %) achieved
CDAI remission at week 36. Of those patients, 187
(91.2 %) were concordant, 2 (1.0 %) were negatively dis-
cordant, and 16 (7.8 %) were positively discordant. These
results are similar to those for Boolean remission, with
the exception that more patients in CDAI remission
were positively discordant.
Relationship between discordance status and remission
An additional analysis found that for patients with posi-
tive discordance, concordance, and negative discordance
at baseline, 44/194 (22.7 %), 193/520 (37.1 %), and 18/48
(37.5 %), respectively, achieved Boolean remission at
week 36, and 44/193 (22.8 %), 145/520 (27.9 %), and 16/
48 (33.3 %), respectively, achieved CDAI remission. In
comparison, for patients with positive discordance, con-
cordance, and negative discordance at week 36, 0/189
(0 %), 250/551 (45.4 %), and 5/18 (27.8 %), respectively,
Table 2 Disease characteristics at baseline and week 36, according to week-36 concordance category (Continued)
Patient general health VAS BL 47.8 (16.9) 40.9 (15.9) 45.7 (22.8) <0.0001
Week 36 36.9 (19.1) 12.4 (13.3) 14.7 (14.4) <0.0001
Δ BL to wk 36 −11.1 (22.4) −28.5 (18.8) −31.1 (22.6) <0.0001
Values are mean (SD). Positive discordance: patient global assessment – physician global assessment ≥2. Negative discordance: patient global assessment – physician
global assessment ≤ –2. Concordance: patient global assessment – physician global assessment = 0 or 1. BL baseline, BPI brief pain inventory, CDAI clinical disease
activity index, CRP C-reactive protein, DAS28 disease activity score based on 28 joint count, ESR erythrocyte sedimentation rate, FACIT-fatigue functional assessment of
chronic illness therapy-fatigue, HAQ-DI health assessment questionnaire disability index, SDAI simplified disease activity index, SJC swollen joint count, TJC tender joint
count, VAS visual analog scale, wk, week. aF-statistic (analysis of variance). bHigher scores indicate less fatigue
Fig. 1 Shifts in discordance categories, baseline to week 36 (n = 762).
Positive discordance: patient global assessment – physician global
assessment ≥2. Negative discordance: patient global assessment –
physician global assessment≤ –2. Concordance: patient global
assessment – physician global assessment = 0 or 1
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achieved Boolean remission at week 36 and 16/189
(8.5 %), 187/555 (33.7 %), and 2/18 (11.1 %), respectively,
achieved CDAI remission.
Correlations and predictors of discordance
The baseline values of BPI, SJC, duration of morn-
ing stiffness, FACIT-fatigue, and patient general
health significantly correlated with week-36 discord-
ance, p < 0.0001 to p < 0.05 (Table 3), although the
correlations were weak (r <0.25). At week 36, DAS28,
duration of morning stiffness, HAQ-DI, FACIT-fatigue,
CDAI, and SDAI correlated significantly but weakly with
discordance, p < 0.0001 for all. BPI and patient general
health demonstrated the strongest correlations, which
were moderate, at week 36 (r = 0.48 and 0.58, respectively,
p < 0.0001 for both).
Baseline predictors of week-36 positive discordance
were patient general health, BPI, and CRP. The odds ratios
(95 % confidence interval) were similar for the full popula-
tion (patient general health: 1.02 (1.00, 1.03), BPI: 1.22
(1.11, 1.35), CRP: 0.98 (0.97, 1.00)) and the subpopulation
of patients who achieved SJC and TJC ≤1 and CRP
≤1 mg/dL at week 36 (patient general health: 1.03 (1.01,
1.04), BPI: 1.24 (1.07, 1.43), CRP: 0.97 (0.94, 1.00)).
WPAI scores
At baseline, mean percent WPAI activity impairment was
higher (greater impairment) for the patients with positive
discordance (51.1 %) than for the patients with concord-
ance (41.3 %) or negative discordance (42.8 %) (p < 0.0001
across means) (Table 4). This continued to week 36, with
mean activity impairment of 35.4 %, 15.1 %, and 25.6 %
for the positive discordance, concordant, and negative dis-
cordance groups, respectively, p < 0.0001. The greatest im-
provement between baseline and week 36 occurred in the
patients who were concordant at week 36. For the sub-
group of patients who were employed at baseline and
36 weeks and had WPAI data (n = 287), the mean percent
impairment while working was higher for the patients
with positive discordance at baseline and 36 weeks (50.0 %
and 26.3 %, respectively) than for the patients with con-
cordance (37.8 % and 10.7 %, respectively) or negative
discordance (42.0 % and 12.0 %, respectively) (p ≤ 0.0026
across means) (Table 4). Similarly, the mean percent over-
all work impairment was higher for the patients with posi-
tive discordance at baseline and 36 weeks (54.6 % and
28.7 %, respectively) than for the patients with concord-
ance (41.5 % and 12.2 %, respectively) or negative discord-
ance (43.7 % and 12.0 %, respectively) (p ≤ 0.0019 across
means). Mean percent work time missed did not differ sig-
nificantly between the concordance categories; it was nu-
merically highest in the positive discordance group at
both baseline and week 36 (Table 4).
Discussion
We evaluated the rates of concordance and discordance
of global disease activity assessments at baseline and
after 36 weeks of open-label, single-arm treatment with
etanercept and methotrexate in patients with moderate
RA who participated in the PRESERVE trial. At baseline,
31.8 % of patient assessments of disease activity were
discordant with the assessments of their physicians. This
Table 3 Correlation between week-36 discordance and measurements of disease at baseline and week 36, and change from baseline to
week 36
Baseline Week 36 Change baseline to week 36
Number Pearson’s r Number Pearson’s r Number Pearson’s r
DAS28 760 −0.0225 762 0.1832*** 760 0.1942***
CRP 754 −0.0561 756 −0.0097 754 0.0523
ESR 763 −0.0630 763 0.0287 763 0.0924*
TJC 760 0.0058 762 0.0449 760 0.0269
SJC 760 −0.1197** 762 −0.0662 760 0.0678
Duration of morning joint stiffness 745 0.0813* 747 0.1456*** 745 −0.0094
BPI 753 0.2268*** 761 0.4784*** 753 0.1854***
HAQ-DI 757 0.0648 762 0.3174*** 757 0.2404***
FACIT-fatigue 753 −0.1437*** 761 −0.3645*** 753 −0.2054***
CDAI 760 0.0116 762 0.1986*** 760 0.1602***
SDAI 751 −0.0068 755 0.1912*** 751 0.1698***
Patient general health VAS 762 0.1826*** 763 0.5784*** 762 0.3542***
Duration of disease 761 −0.0402 na na na na
Discordance is defined as patient global assessment – physician global assessment. BPI brief pain inventory, CDAI clinical disease activity index, CRP C-reactive protein,
DAS28 disease activity score based on 28 joint count, ESR erythrocyte sedimentation rate, FACIT-fatigue functional assessment of chronic illness therapy-fatigue, HAQ-DI
health assessment questionnaire disability index, na not available, SDAI simplified disease activity index, SJC swollen joint count, TJC tender joint count, VAS visual analog
scale. *p < 0.05, **p < 0.001, ***p < 0.0001
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Table 4 Work productivity activity impairment questionnaire for rheumatoid arthritis (WPAI:RA) results at baseline, week 36, and change from baseline to week 36, according to
week-36 concordance category
All patients Positive discordance (n = 187) Concordance (n = 549) Negative discordance (n = 18)
Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) P valuea








































Positive discordance (n = 76) Concordance (n = 206) Negative discordance (n = 5)
Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) P valuea















































































Positive discordance (n = 74) Concordance (n = 200) Negative discordance (n = 5)
Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) Mean (SD) Median (Q1, Q3) p valuea







































Activity impairment includes all patients who had both baseline and week 36 data for this parameter. The remaining WPAI parameters include only patients who were employed and had WPAI data at both baseline
and week 36. A total of 305 patients were employed at both baseline and week 36; individual WPAI parameters differ due to missing baseline or week 36 values. Positive discordance: patient global assessment –
physician global assessment ≥2. Negative discordance: patient global assessment – physician global assessment ≤ –2. Concordance: patient global assessment – physician global assessment = 0 or 1. Δ change; Q1














represents a disconnect between the patient and phys-
ician in verbal and non-verbal cues about how RA is af-
fecting the patient. In most cases, discordance reflected
higher ratings of disease activity by patients.
When comparing concordance in this study to others
that used a similar method of measurement, the rate of
concordance was comparable to several [1, 3, 4] and higher
than other studies [2, 5]. As with other studies, we found
that pain was an important contributor to the patient global
assessment and discordance [2–5, 9, 11–13, 15]. We also
noted that patients with relatively high levels of inflamma-
tory activity, as assessed by an objective measure such as
CRP, had a higher level of concordance than patients with
lower levels of inflammation, similar to several other studies
[1, 4, 5, 9, 12]. In our analysis, baseline CRP was highest in
patients with concordance, with a mean of 13.4 mg/L, com-
pared with 9.9 mg/L for positive discordance and 8.1 mg/L
for negative discordance. This suggests that patients with
high levels of inflammation tend to focus on indicators of
potential joint damage, similar to clinicians.
At week 36, the rate of discordance was 27.1 % overall.
Among the subgroup of 442 patients who achieved SJC
and TJC ≤1 and CRP ≤1 mg/dL, the discordance rate
was lower but still substantial at 22.4 %. This result pro-
vides additional evidence that even when the disease is
controlled, pain may still be present, resulting in a con-
siderable difference between patient and physician view-
points [15]. Not surprisingly, for the 255 patients in this
subgroup who also reported a patient global assessment
≤1 (thereby achieving a Boolean remission), the rate of
discordance was 2 %. This is entirely negative discord-
ance, and is comparable to the negative discordance of
2.4 % for the overall population. The overall decrease in
discordance from 31.8 % at baseline to 27.1 % at week
36 occurred in the context of improved disease control.
This may be a result that is independent of the gap in
communication, or it may be due to the physician be-
coming more adept at interpreting patient cues, or pa-
tients becoming more expressive of how they feel.
This analysis of the PRESERVE trial provides a novel
perspective in several ways. First, it focuses on patients
with moderate RA (DAS28 >3.2 and ≤5.1) who received
therapy with etanercept and methotrexate. Many previ-
ously reported studies did not specify the extent of disease
activity, nor did they examine discordance following treat-
ment with a tumor necrosis factor inhibitor. As the major-
ity of patients seen in clinical practice have low or
moderate RA activity [36, 37], the data presented in this
report are relevant to most patients.
We also assessed the relationship between discordance,
activity impairment, and work productivity. Previous stud-
ies have found that moderate RA (and even mild RA) is as-
sociated with work impairment [23, 24, 27]. Additionally,
one study of patients with RA and other inflammatory and
noninflammatory rheumatic diseases found a significant
association between discordance and not working [2]. We
examined this association more closely by using the
WPAI:RA to measure four components of work productiv-
ity: activity impairment, absenteeism, presenteeism, and
overall work impairment. All three components of the
WPAI:RA related to employment were highest (i.e.,
worst) in patients with positive discordance; for two
of these components the difference was statistically
significant. These results suggest that discrepancies
between patient and physician assessments of disease
not only are associated with poorer clinical outcomes,
but may also extend to other domains of a patient’s
life such as work productivity, which could potentially
have an economic impact on patients and society.
A strength of this study is that it evaluated data from a
clinical trial population, thereby ensuring that all patients
were managed in a consistent manner and data were col-
lected at fixed intervals. This includes collection of work
productivity data using a validated instrument, the
WPAI:RA. Additionally, investigators completed the phys-
ician global assessment prior to having access to CRP
values for that visit. This removed the potential for the CRP
results to bias the physician assessment. In the clinic, pa-
tients sometimes bring their CRP or ESR results with them.
Therefore, the current study may more accurately reflect
the similarities and differences between patient global as-
sessments and physician global assessments than in the
clinic [9, 38].
This study has several limitations. Importantly, we were
limited to the assessments that were used in the clinical
trial. Although of interest, we were not able to evaluate the
effect of depression or cognitive impairment on discord-
ance because no validated measurement tool was used in
the trial. In addition, as this was a clinical trial, the results
may not be generalizable to all patients with RA. This study
excluded patients with mild or severe disease activity and
those with certain comorbid conditions. As a clinical trial,
physicians could not modify medication regimens at will;
instead it was necessary to follow the study protocol. Also,
patients who left the study for any reason were not
followed, and so we were unable to determine whether
their concordance status changed over time.
Conclusions
The results of our analysis demonstrated that in patients
with moderately active RA, the rate of concordance of
patient and physician global assessments increased after
36 weeks of treatment with etanercept and methotrex-
ate. Discordance significantly correlated with several
clinical endpoints and was associated with decreased
work productivity. Additional research into verbal and
nonverbal patient/physician communication is needed to
fully understand the discrepancies.
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